Bézard M, Kharoubi M, Galat A, et al. - Given that hereditary (ATTRv) and wild‐type (ATTRwt) transthyretin amyloidosis represent severe and fatal systemic disorders, and recently, a reduction in the relative risk of death in ATTR amyloidosis with cardiomyopathy has been shown to be provided by tafamidis in the Phase III ATTR‐ACT trial, therefore, researchers determined the clinical features of ATTR amyloidosis in a real‐life population vs the population included in the ATTR‐ACT trial. They also investigated the effect of tafamidis use on major cardiovascular outcome (MCO)‐free survival time without cardiac decompensation, heart transplant, or mortality. The inclusion criteria of the ATTR‐ACT trial was satisfied by 467 (72%) patients. For 631 patients experiencing cardiomyopathy, a longer median MCO‐free survival time was reported in relation to tafamidis treatment. In a large cohort comprising ATTRwt and ATTRv patients, representative of the inclusion criteria of the ATTR‐ACT trial, tafamidis treatment was shown to be related to a lower occurrence of cardiovascular outcomes in a real‐life population.